Last $0.11 USD
Change Today -0.0263 / -18.79%
Volume 79.0K
BIEI On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

premier biomedical inc (BIEI) Snapshot

Open
$0.13
Previous Close
$0.14
Day High
$0.14
Day Low
$0.11
52 Week High
02/11/14 - $2.60
52 Week Low
09/19/14 - $0.11
Market Cap
2.4M
Average Volume 10 Days
17.6K
EPS TTM
--
Shares Outstanding
20.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PREMIER BIOMEDICAL INC (BIEI)

Related News

No related news articles were found.

premier biomedical inc (BIEI) Related Businessweek News

No Related Businessweek News Found

premier biomedical inc (BIEI) Details

Premier Biomedical, Inc., a research-based company, develops and markets medications and procedures for health issues worldwide. It develops sequential-dialysis technique for the treatment of alzheimer’s disease, amyotrophic lateral sclerosis, blood sepsis and viremia, leukemia, and other life-threatening cancers; and Feldetrex, a drug candidate for multiple sclerosis, fibromyalgia, and traumatic brain injury. The company markets its products to pharmaceutical firms directly, as well as through publication in medical journals. It has a collaborative agreement with the University of Texas at El Paso to develop a series of research and development programs for its sequential-dialysis technology in the areas of alzheimer's disease, traumatic brain injury, chronic pain syndrome, fibromyalgia, multiple sclerosis, amyotrophic lateral sclerosis, blood sepsis, cancer, heart attacks, and strokes. The company was founded in 2010 and is based in El Paso, Texas.

premier biomedical inc (BIEI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

premier biomedical inc (BIEI) Key Developments

Premier Biomedical, Inc. Announces United States Patent Office Approves a Patent on Potential Multi-Billion Dollar Drug for the Treatment of Fibromyalgia and Neuralgia

Premier Biomedical, Inc. announced that the United States Patent Office approved a patent on their proprietary medication 'Feldetrex (TM)', which is designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is drafting a protocol to conduct a double-blind, placebo-controlled comparison of this medication and the FDA-approved regimen for these concerns and will be submitting it for IRB approval in the near future.

Premier Biomedical to Design Clinical Trial Equipment in Partnership with Printed Device Concepts

Premier Biomedical revealed the launch of an agreement to design and fabricate its patent-pending Sequential Dialysis Machine that is critical to advancing its medications and procedures via anticipated clinical trials beginning as early as this calendar year. The company has signed the agreement with Printed Device Concepts (PDC) of El Paso, Texas.

Premier Biomedical and William Beaumont Medical Center Establish Cooperative Research and Development Agreement for Major Medical Treatments

Premier Biomedical, Inc. announced that a Cooperative Research and Development Agreement (CRADA) with William Beaumont Army Medical Center has been signed and approved by the US Army Clinical Investigation Regulatory Office (CIRO) for implementation. Under terms of the Agreement, WBAMC will conduct advanced and clinical research for Premier Biomedical's medical treatments targeting the prevention of suicidal ideation and clinical depression, and therapies for traumatic brain injury induced maladies including posttraumatic stress disorder (PTSD) and suicide. The U.S. Department of Defense (DOD) will have unlimited access to Premier's technologies at the original licensing cost for life. Premier will have direct access to the DOD's technical expertise in advanced model creation and clinical testing to advance the development of its technologies beyond the laboratory.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIEI:US $0.11 USD -0.0263

BIEI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIEI.
View Industry Companies
 

Industry Analysis

BIEI

Industry Average

Valuation BIEI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PREMIER BIOMEDICAL INC, please visit www.premierbiomedicalinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.